ALNY - Alnylam Pharmaceuticals

-

$undefined

N/A

(N/A)

Alnylam Pharmaceuticals NasdaqGS:ALNY Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Location: 675 West Kendall Street, Cambridge, MA, 02142, United States | Website: https://www.alnylam.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

39.8B

Cash

2.632B

Avg Qtr Burn

-11.28M

Short % of Float

2.93%

Insider Ownership

3.83%

Institutional Own.

97.51%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AMVUTTRA (Vutrisiran) Details
Transthyretin amyloidosis, Transthyretin Amyloid Cardiomyopathy

Approved

Update

Leqvio® (inclisiran) Details
Transthyretin amyloidosis, Atherosclerotic cardiovascular disease

Approved

Quarterly sales

Approved

Quarterly sales

OXLUMO® (lumasiran) Details
Primary hyperoxaluria

Approved

Quarterly sales

ONPATTRO® (Patisiran) Details
Transthyretin amyloidosis

Approved

Quarterly sales

AMVUTTRA (Vutrisiran) Details
Transthyretin amyloidosis, Cardiomyopathy

Approved

Quarterly sales

ONPATTRO® (Patisiran) Details
Transthyretin amyloidosis

sNDA

Resubmission

Nucresiran (ALN-TTRsc04) Details
Transthyretin amyloidosis

Phase 3

Initiation

Mivelsiran (ALN-APP) Details
Cerebral Amyloid Angiopathy

Phase 2

Data readout

Phase 2

Data readout

Zilebesiran (ALN-AGT) Details
Metabolic disorder, Pulmonary arterial hypertension

Phase 2

Data readout

Phase 1

Update

ALN-HSD Details
Non-alcoholic steatohepatitis

Phase 1

Update

ALN-PNP Details
Non-alcoholic steatohepatitis

Phase 1

Update

ALN-KHK Details
Type 2 diabetes

Phase 1a

Data readout

Failed

Discontinued

ALN-XDH Details
Arthritis, Chronic refractory gout

Failed

Discontinued